The potential role of Marginal Structural Models (MSMs) in testing the effectiveness of antidepressants in the treatment of patients with major depression in everyday clinical practice

World Journal of Biological Psychiatry

Volumn 14, Issue 5, 2013, Pages 386-395

  Severus, Emanuel ^a   Lipkovich, Ilya ^b   Seemüller, Florian ^a   Obermeier, Michael ^a   Grunze, Heinz ^c   Bernhard, Britta ^a   Dittmann, Sandra ^a   Riedel, Michael ^a   Möller, Hans Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b ELI LILLY AND COMPANY   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Evidence based practice; Major depression; Marginal structural models; Randomized controlled clinical trials as topic; Treatment outcome

Indexed keywords

ANTIDEPRESSANT AGENT;

ANALYTICAL ERROR; ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MARGINAL STRUCTURAL MODEL; MENTAL PATIENT; NULL HYPOTHESIS; OUTCOME ASSESSMENT; PROBABILITY; PSYCHOPHARMACOTHERAPY; RELAPSE; REMISSION; RISK; STATISTICAL MODEL; WATCHFUL WAITING;

EID: 84880775928     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2011.619205     Document Type: Article

References (41)

1. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, et al. 2003. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR * D) study. Psychiatr Clin North Am 26(2):457- 494, x.
2. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J. 2010. Antidepressant drug effects and depression severity: A patient-level meta-analysis. J Am Med Assoc 303(1):47-53.
3. Hegerl U, Mergl R. 2010. The clinical signifi cance of antidepressant treatment effects cannot be derived from placebo-verum response differences. J Psychopharmacol 24(4):445-448.
4. Hernán MA, Brumback B, Robins JM. 2000. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11(5):561-570.
5. Hernán MA, Brumback BA, Robins JM. 2001. Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Stat Assoc 96(454):440-448.
6. Hernán MA, Brumback BA, Robins JM. 2002. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med 21(12):1689-1709.
7. Hernán MA, Lanoy E, Costagliola D, Robins JM. 2006. Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol 98(3):237-242.
8. Hrobjartsson A, Gotzsche PC. 2001. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. New Engl J Med 344(21):1594-1602.
9. Kaptchuk TJ, Shaw J, Kerr CE, Conboy LA, Kelley JM, Csordas TJ, et al. 2009. 'Maybe I made up the whole thing': Placebos and patients'experiences in a randomized controlled trial. Cult Med Psychiatry 33(3):382-411.
10. Kennedy SH, Lam RW, Parikh SV, Patten SB, Ravindran AV. 2009. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J Affect Disord 117(Suppl 1):S1- 2.
11. Kim SW, Grant JE, Eckert ED, Faris PL, Hartman BK. 2006. Pathological gambling and mood disorders: Clinical associations and treatment implications. J Affect Disord 92(1):109-116.
12. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. 2008. Initial severity and antidepressant benefi ts: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5(2):e45.
13. Krogsboll LT, Hrobjartsson A, Gotzsche PC. 2009. Spontaneous improvement in randomised clinical trials: Meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. BMC Med Res Methodol 9:1.
14. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. 2009. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 117(Suppl 1):S26- 43.
15. Loh A, Simon D, Wills CE, Kriston L, Niebling W, Harter M. 2007. The effects of a shared decision-making intervention in primary care of depression: A cluster-randomized controlled trial. Patient Educ Couns 67(3):324-332.
16. Moller HJ. 2005. Are placebo-controlled studies required in order to prove effi cacy of antidepressants? World J Biol Psychiatry 6(3):130-131.
17. Moller HJ. 2008. Isn't the effi cacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008. Eur Arch Psychiatry Clin Neurosci 258(8):451-455.
18. Moller HJ. 2009. Antidepressants: Controversies about their effi -cacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. World J Biol Psychiatry 10(3):180-195.
19. Moller HJ, Maier W. 2010. Evidence-based medicine in psychopharmacotherapy: Possibilities, problems and limitations. Eur Arch Psychiatry Clin Neurosci 260(1):25-39.
20. Moodie EEM, Delaney JAC, Levebre G, Platt RW. 2008. Missing confounding data in marginal structural models: A comparison of inverse probability weighting and multiple imputation. Int J Biostat 4(1). Article 13. http://www.bepress.com/ijb/vol4/iss1/13.
21. Mortimer KM, Neugebauer R, van der Laan M, Tager IB. 2005. An application of model-fi tting procedures for marginal structural models. Am J Epidemiol 162(4):382-388.
22. Muller-Oerlinghausen B. 1994. Multidimensional assessment of acute and long-term effects in antidepressant drug trials. Pharmacopsychiatry 27(Suppl 1):18-20.
23. Murphy SA, van der Laan MJ, Robins JM. 2001. Marginal mean models for dynamic regimes. J Am Stat Assoc 96(456):1410-1423.
24. Nutt DJ, Davidson JR, Gelenberg AJ, Higuchi T, Kanba S, Karamustafalioglu O, et al. 2010. International consensus statement on major depressive disorder. J Clin Psychiatry 71(Suppl E1):e08.
25. Otto MW, Nierenberg AA. 2002. Assay sensitivity, failed clinical trials, and the conduct of science. Psychother Psychosom 71(5):241-243.
26. Parikh SV, Segal ZV, Grigoriadis S, Ravindran AV, Kennedy SH, Lam RW, Patten SB. 2009. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord 117(Suppl 1):S15- 25.
27. Parker G, Anderson IM, Haddad P. 2003. Clinical trials of antidepressant medications are producing meaningless results. Br J Psychiatry 183:102-104.
28. Patten SB, Kennedy SH, Lam RW, ÓDonovan C, Filteau MJ, Parikh SV, Ravindran AV. 2009. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classifi cation, burden and principles of management. J Affect Disord 117(Suppl 1):S5- 14.
29. Posternak MA, Miller I. 2001. Untreated short-term course of major depression: A meta-analysis of outcomes from studies using wait-list control groups. J Affect Disord 66(2- 3):139-146.
30. Quitkin FM, Rabkin JG, Gerald J, Davis JM, Klein DF. 2000. Validity of clinical trials of antidepressants. Am J Psychiatry 157(3):327-337.
31. Riedel M, Strassnig M, Muller N, Zwack P, Moller HJ. 2005. How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials? Eur Arch Psychiatry Clin Neurosci 255(2):143-148.
32. Rihmer Z, Gonda X. 2008. Is drug-placebo difference in shortterm antidepressant drug trials on unipolar major depression much greater than previously believed? J Affect Disord 108(3):195-198.
33. Robins JM, Greenland S, Hu F. 1999. Estimation of the causal effect of a time-varying exposure on the marginal mean of a repeated binary outcome. J Am Stat Assoc 94(447):687-700.
34. Robins JM, Hernán MA, Brumback B. 2000. Marginal structural models and causal inference in epidemiology. Epidemiology 11(5):550-560.
35. Rutherford BR, Sneed JR, Roose SP. 2009. Does study design infl uence outcome?. The effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom 78(3):172-181.
36. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. 1996. Evidence based medicine: What it is and what it isn't. BMJ 312(7023):71-72.
37. Seemuller F, Moller HJ, Obermeier M, Adli M, Bauer M, Kronmuller K, et al. 2010. Do effi cacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials. J Clin Psychiatry 71(11):1425-1433.
38. Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, Lanctot KL. 2010. Does inclusion of a placebo arm infl uence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 71(3):270-279.
39. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. 2008. Selective publication of antidepressant trials and its infl uence on apparent effi cacy. New Engl J Med 358(3): 252-260.
40. Turner EH, Rosenthal R. 2008. Effi cacy of antidepressants. Br Med J 336(7643):516-517.
41. Wisniewski SR, Rush AJ, Nierenberg AA, Gaynes BN, Warden D, Luther JF, et al. 2009. Can phase III trial results of antidepressant medications be generalized to clinical practice? A star * d report. Am J Psychiatry 166(5):599-607.